Suppr超能文献

抗中性粒细胞胞质抗体相关性血管炎发病机制概述。

Overview of the Pathogenesis of ANCA-Associated Vasculitis.

机构信息

Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, N.C., USA.

出版信息

Kidney Dis (Basel). 2016 Mar;1(4):205-15. doi: 10.1159/000442323. Epub 2015 Dec 3.

Abstract

BACKGROUND

Antineutrophil cytoplasmic autoantibodies (ANCA) are associated with a spectrum of necrotizing vasculitis including granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited necrotizing and crescentic glomerulonephritis. Clinical observations and in vitro and in vivo experimental evidence strongly indicate that ANCA are pathogenic.

SUMMARY

The etiology and pathogenesis of ANCA-associated vasculitis (AAV) are multifactorial, with contributions from genetic factors, environmental exposures, infections, characteristics of the innate and adaptive immune system, and the intensity and duration of the injury. Acute vascular inflammation is induced when resting neutrophils that have ANCA autoantigens sequestered in cytoplasmic granules are exposed to priming factors - for example, cytokines induced by infection or phlogogenic factors released by complement activation - that cause the release of ANCA antigens on the surface of neutrophils and in the microenvironment around the neutrophils. ANCA bind to these ANCA antigens, which activates neutrophils by Fcγ receptor engagement and F(ab')2 binding at the neutrophil cell surface. ANCA-activated neutrophils release factors that activate the alternative complement pathway, which generates C5a, a chemoattractant for neutrophils; C5a also primes the arriving neutrophils for activation by ANCA. Activated neutrophils adhere to and penetrate vessel walls, and they release toxic oxygen radicals and destructive enzymes that cause apoptosis and necrosis of the neutrophils as well as of the adjacent vessel wall cells and matrix.

KEY MESSAGES

Patients with active AAV have ongoing asynchronous onsets of countless acute lesions, with each lesion evolving through stereotypical phases within 1 or 2 weeks. Induction of remission results in termination of new waves of acute lesions and allows all lesions to progress to scarring or resolution.

摘要

背景

抗中性粒细胞胞浆抗体 (ANCA) 与多种坏死性血管炎相关,包括肉芽肿性多血管炎、显微镜下多血管炎、嗜酸性肉芽肿性多血管炎和肾局限性坏死性和新月体性肾小球肾炎。临床观察和体外及体内实验证据强烈表明 ANCA 具有致病性。

概述

抗中性粒细胞胞浆抗体相关性血管炎 (AAV) 的病因和发病机制是多因素的,涉及遗传因素、环境暴露、感染、固有和适应性免疫系统特征以及损伤的强度和持续时间。当静息的中性粒细胞中含有 ANCA 自身抗原的细胞质颗粒被暴露于启动因子(例如感染诱导的细胞因子或补体激活释放的趋化因子)时,就会诱导急性血管炎症,导致中性粒细胞表面和周围微环境中 ANCA 抗原的释放。ANCA 与这些 ANCA 抗原结合,通过 Fcγ 受体结合和 F(ab')2 在中性粒细胞表面的结合激活中性粒细胞。ANCA 激活的中性粒细胞释放激活替代补体途径的因子,该途径生成 C5a,一种中性粒细胞的趋化因子;C5a 还使到达的中性粒细胞通过 ANCA 被激活。激活的中性粒细胞黏附和穿透血管壁,并释放有毒的氧自由基和破坏性酶,导致中性粒细胞以及相邻血管壁细胞和基质的凋亡和坏死。

关键信息

患有活动性 AAV 的患者有无数急性病变的持续异步发作,每个病变在 1 或 2 周内通过典型阶段进展。诱导缓解可导致新一波急性病变的终止,并使所有病变进展为瘢痕或消退。

相似文献

1
Overview of the Pathogenesis of ANCA-Associated Vasculitis.
Kidney Dis (Basel). 2016 Mar;1(4):205-15. doi: 10.1159/000442323. Epub 2015 Dec 3.
2
Complement in ANCA-associated vasculitis.
Semin Nephrol. 2013 Nov;33(6):557-64. doi: 10.1016/j.semnephrol.2013.08.006.
4
Antineutrophil cytoplasmic autoantibodies and associated diseases: a review.
Am J Kidney Dis. 1990 Jun;15(6):517-29. doi: 10.1016/s0272-6386(12)80521-x.
5
Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies.
Contrib Nephrol. 2011;169:211-220. doi: 10.1159/000314776. Epub 2011 Jan 20.
6
Pathogenesis of ANCA-Associated Pulmonary Vasculitis.
Semin Respir Crit Care Med. 2018 Aug;39(4):413-424. doi: 10.1055/s-0038-1673386. Epub 2018 Nov 7.
7
Complement system activation in ANCA vasculitis: A translational success story?
Mol Immunol. 2015 Nov;68(1):53-6. doi: 10.1016/j.molimm.2015.06.005.
8
Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations.
Semin Arthritis Rheum. 1995 Dec;25(3):143-59. doi: 10.1016/s0049-0172(95)80027-1.
9
New advances in the pathogenesis of ANCA-associated vasculitides.
Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S108-14.
10
Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies.
J Am Soc Nephrol. 2006 May;17(5):1235-42. doi: 10.1681/ASN.2005101048. Epub 2006 Apr 19.

引用本文的文献

1
Pauci-immune glomerulonephritis: Post-COVID kidney disease continues to reappear, a case report.
Sci Prog. 2025 Jul-Sep;108(3):368504251364950. doi: 10.1177/00368504251364950. Epub 2025 Aug 4.
3
Can we cure vasculitis?
Curr Opin Immunol. 2025 Jul 28;96:102618. doi: 10.1016/j.coi.2025.102618.
6
Complement as a major mediator of ANCA vasculitis and a target for precision therapy.
Expert Rev Clin Immunol. 2025 Jan;21(1):45-53. doi: 10.1080/1744666X.2024.2405170. Epub 2024 Sep 18.
7
Antineutrophil Cytoplasmic Antibody Vasculitis after Coronary Artery Bypass Grafting.
Case Rep Surg. 2024 Aug 12;2024:1212538. doi: 10.1155/2024/1212538. eCollection 2024.
8
Nasal Microbiome in Granulomatosis with Polyangiitis Compared to Chronic Rhinosinusitis.
Diagnostics (Basel). 2024 Aug 2;14(15):1673. doi: 10.3390/diagnostics14151673.
9
Thrombosis in vasculitis: An updated review of etiology, pathophysiology, and treatment.
Heliyon. 2024 May 1;10(12):e30615. doi: 10.1016/j.heliyon.2024.e30615. eCollection 2024 Jun 30.
10
Antineutrophil cytoplasmic antibody positivity incidence before and during COVID-19 pandemic.
Rheumatol Int. 2024 Oct;44(10):1935-1940. doi: 10.1007/s00296-024-05596-3. Epub 2024 Apr 24.

本文引用的文献

2
Myeloperoxidase Peptide-Based Nasal Tolerance in Experimental ANCA-Associated GN.
J Am Soc Nephrol. 2016 Feb;27(2):385-91. doi: 10.1681/ASN.2015010089. Epub 2015 Jun 5.
3
Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis.
Arthritis Res Ther. 2015 May 21;17(1):129. doi: 10.1186/s13075-015-0656-8.
5
M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN.
Clin J Am Soc Nephrol. 2015 Jan 7;10(1):54-62. doi: 10.2215/CJN.03230314. Epub 2014 Dec 16.
6
ANCAs are also antimonocyte cytoplasmic autoantibodies.
Clin J Am Soc Nephrol. 2015 Jan 7;10(1):4-6. doi: 10.2215/CJN.11501114. Epub 2014 Dec 16.
7
Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Nephron Clin Pract. 2014;128(3-4):243-9. doi: 10.1159/000368580. Epub 2014 Nov 14.
9
Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.
Curr Opin Rheumatol. 2014 Jan;26(1):42-9. doi: 10.1097/BOR.0000000000000014.
10
C5a receptor (CD88) blockade protects against MPO-ANCA GN.
J Am Soc Nephrol. 2014 Feb;25(2):225-31. doi: 10.1681/ASN.2013020143. Epub 2013 Oct 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验